RWE and Patient-Centered Outcomes
Widespread availability of real-world data has enabled the generation of evidence and insights that benefit patients, providers, plans, and industry. When that evidence reflects patient outcomes, it provides an invaluable perspective on the consumer experience. Explore our real-world evidence (RWE) analyses and guidance to support your strategic decisions.
2023 Top HEOR Trends: HEOR as a Differentiator vs. Commodity
Avalere experts dive into Trend #8: HEOR as a Differentiator vs. a Commodity and explore the need for tailored evidence generation planning.
Video: HEOR as a Differentiator Versus a Commodity
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #8: HEOR as a Differentiator Versus a Commodity.
Video: Reevaluating Value Assessment for HEOR in 2023
In the next installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #7: Value Assessment.
Video: Contextualizing AI for HEOR in 2023
In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #6: Artificial Intelligence.
Video: Embedding Patient-Centric Principles in Research, Quality, and Care Delivery
In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #5, patient engagement and centricity in healthcare decision making.
HEOR Trends: Patient-Centricity
The patient perspective should be incorporated across the care spectrum, including clinical research and drug development, care decisions, outcomes measures, and how value is defined.
2023 Top Trends in Health Economics and Outcomes Research
Avalere identified the top trends in HEOR and key implications for life sciences companies to consider for their 2024 strategic plans.
Video: 2023 Top Trends in Health Economics and Outcomes Research
Avalere identified the top trends in health economics and outcomes research in 2023 and beyond. In this video, Avalere experts dive into a few of the key trends in HEOR that are significantly shaping the landscape.
Video: Spotlight on Avalere’s Evidence and Strategy Practice
Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.
Decentralized Clinical Trials for Rare Disease Treatments
Decentralized clinical trials offer the potential to democratize rare disease research, advancing drug development and improving patient experiences.
Use of Patient-Centered Outcomes in ICER Assessments
Avalere assessed the current use of patient-centered outcomes in ICER evidence reports and determined the patient voice minimally influences modeling results.
How Can Patients and Caregivers Participate in Negotiation?
Recently released guidance and a second draft Negotiation Data Elements ICR introduce several opportunities for patients and caregivers to shape negotiation.
Implementation Science Integrates Evidence into Care
Despite proven benefits, evidence-based interventions are rarely adopted. Implementation science can support the integration of such interventions in routine healthcare.
US Makes Majority of API by Dollar Value in US-Consumed Medicines
Data analysis finds that 53% of the API, in dollars, used in domestically consumed medicines came from the US in 2021, and 85% came from the US or Europe.
ISPOR 2023 Presentation: The Future of Value and Evidence Strategy
Avalere’s expert presentations at ISPOR described the IRA’s impact on evidence strategy and highlighted a recent study to capture total disease burden.
What’s Next for Patient-Centered Value?
A significant push towards patient-centered value has occurred in recent years, yet a validated instrument to collect patient-centered data has not been established. The Patient Perspective Value Framework (PPVF) Initiative offers an approach for addressing this missing piece.
Infusing the Patient Perspective into Value Assessment
Current value assessment methods do not effectively and quantitatively include patients’ perspectives in the evaluation of treatment value.
Survey Finds 58% of Payers Use Outcomes-Based Contracts
In 2022, over half of payers had at least one outcomes-based contract (OBC) and used claims-based outcomes, despite acknowledging the limitations of using claims to measure clinical benefit.
RWE Considerations Throughout Product Development Cycle
Drug manufacturers can use real-world evidence (RWE) before and after approval to advance product development and adoption.
Video: The Future of Patient-Centric Value
Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.